Title |
Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire
|
---|---|
Published in |
Malaria Journal, November 2014
|
DOI | 10.1186/1475-2875-13-439 |
Pubmed ID | |
Authors |
Offianan A Toure, Serge B Assi, Tiacoh L N’Guessan, Gbessi E Adji, Aristide B Ako, Marie J Brou, Marie F Ehouman, Laeticia A Gnamien, M’Lanhoro AA Coulibaly, Baba Coulibaly, Sylvain Beourou, Issiaka Bassinka, Adama Soumahoro, Florence Kadjo, Mea A Tano |
Abstract |
Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and second-line treatments for uncomplicated falciparum malaria in Cote d'Ivoire. Constant monitoring by National Malaria Control Programme (NMCP) of drug efficacy is an important tool in establishing rational anti-malarial drug policies in Cote d'Ivoire. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Burkina Faso | 1 | 1% |
Unknown | 72 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 19% |
Student > Ph. D. Student | 13 | 18% |
Student > Master | 10 | 14% |
Student > Doctoral Student | 5 | 7% |
Student > Bachelor | 4 | 5% |
Other | 11 | 15% |
Unknown | 17 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 24% |
Agricultural and Biological Sciences | 8 | 11% |
Nursing and Health Professions | 7 | 9% |
Biochemistry, Genetics and Molecular Biology | 6 | 8% |
Social Sciences | 6 | 8% |
Other | 10 | 14% |
Unknown | 19 | 26% |